TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01170650

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC145
Description: IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)
Description: 50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)
Description: 50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC20
Description: During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EC20
Description: During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
Study: NCT00008177

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: iodine I 131 monoclonal antibody BC8
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo total-body irradiation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplantation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given orally or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given orally or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04142827

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Humidification
Description: myAirvo2 gives at home for long therapy treatment
Study: NCT02583269

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01135498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: Oral repeating dose
Study: NCT01849874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162, MEK inhibitor; oral
Description: multiple dose, single schedule
Study: NCT02583269

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscadine Grape Skin Extract
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscadine Grape Skin Extract
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscadine Grape Skin Extract
Description: Given PO
Study: NCT01849874

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's choice chemotherapy
Description: Patients will receive one of the following chemotherapies as determined by the physician:~* Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)~* Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)~* Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)
Study: NCT02583269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscadine Grape Skin Extract
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Muscadine Grape Skin Extract
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03165097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-709478
Description: Hard gelatine capsules for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching ACT-709478 capsules

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam
Description: Midazolam oral solution (2 mg/mL) applied with a syringe
Study: NCT02583269

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03990974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: postoperative antimicrobial prophylaxis
Description: The drugs are all common antibiotics used to prevent postoperative infection in each hospital.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No postoperative antimicrobial prophylaxis
Description: Patients will receive no antibiotics after hepatectomy unless necessary.
Study: NCT03875417

Intervention type: PROCEDURE
Intervention: liver resection
Description: resection of one or more HCC nodules within the liver

Intervention type: PROCEDURE
Intervention: liver resection
Description: resection of one or more HCC nodules within the liver

Intervention type: PROCEDURE
Intervention: Thermic ablation
Description: ablation of HCC nodule through a percutaneous needle, by using radiofrequency or microwaves

Intervention type: PROCEDURE
Intervention: Transcatheter arterial chemoembolization
Description: embolization of HCC nodule via drug-eluted microbeads.
Study: NCT00005850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 80 mg/m2 administered by intravenous (IV) over 30 minutes on Day 1 following the gemcitabine infusion. Treatment repeated every 21 days for a total of 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoxetine
Description: 10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: 1000 mg/m2 intravenous (IV) administered by IV over 30 minutes on days 1 and 8. Repeat treatment every 21 days for a total of 6 cycles.
Study: NCT01288430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-2248
Description: Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
Study: NCT02528227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Know Your Baby Language Curriculum
Description: Early language activities that parents can do with their infants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reading Aloud Language Curriculum
Description: Early language activity that parents can do with their infants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sing A Long Language Curriculum
Description: Early language activity that parents can do with their infants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mimicking First Sounds Language Curriculum
Description: Early language activity that parents can do with their infants

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language Games and Narrating Your Day Language Curriculum
Description: Early language activity that parents can do with their infants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Feeding Safety
Description: Part of Health and Safety Curriculum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Car Seat Safety
Description: Part of Health and Safety Curriculum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bath Safety
Description: Part of Health and Safety Curriculum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Back to Sleep/SIDS prevention
Description: Part of Health and Safety Curriculum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Taking a Temperature and Signs of Infection
Description: Part of Health and Safety Curriculum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Infection Control Measures and Vaccine Information
Description: Part of Health and Safety Curriculum
Study: NCT03165097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-709478 combined with midazolam
Description: Hard gelatine capsules for oral administration (ACT-709478) to be taken first followed by Midazolam oral solution (2 mg/mL) applied with a syringe
Study: NCT03708146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 5-1058
Description: 25 mg and 100 mg tablets; Oral, once-daily, from Day 1 to Day 10. In Cohorts 1, 3, 5, 7 and 9 (fasted), BIA 5-1058 will be orally administered in the morning after a minimum of 8 h fast. Subjects will remain fasted until 4 h post-dose and will receive lunch approximately 4 h after dosing.~In Cohorts 2, 4, 6, 8 and 10 (fed), BIA 5-1058 will be orally administered in the morning after a moderate breakfast (containing approximately 550 kcal with fat contributing approximately 150 kcal). The meal should be consumed over a maximum period of 25 min, with dosing occurring 30 min after the start of the meal.~Each dose will be administered with 240 mL water.
Study: NCT02375802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose-derived stromal cells
Description: Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adipose-derived stromal cells
Study: NCT03844737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisuXL®
Description: Treatment of discomfort forms of the ocular surface, in professional water-polo athletes exposed to pool water for prolonged periods.
Study: NCT02429440

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peptide vaccine
Description: subcutaneous

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peptide vaccine
Description: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Macrophage Colony Stimulating Factor
Description: intradermal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montanide ISA-51
Description: subcutaneous
Study: NCT04377568

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent plasma (CP)
Description: Participants will receive one infusion of convalescent plasma proportional to their weight (10 mL/kg), up to a maximum of 500 mL
Study: NCT00847314

Intervention type: DRUG
Intervention: Testosterone Undeconate (Nebido-R, BAY86-5037)
Description: Male patients \> 35yrs in medical practices fulfilling all criteria for documentation.
Study: NCT01030900

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath
Description: campath plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and rituximab every 3 weeks for up to 6 cycles

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) and campath every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH
Description: Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) plus rituximab and campath every 3 weeks for up to 6 cycles
Study: NCT04628624

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: 8 week supplementation period, with participants consuming 2 capsules per day containing potato starch

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GTE 1
Description: 8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract (571mg/d)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GTE 2
Description: 8 week supplementation period, with participants consuming 2 capsules per day containing green tea extract with additional antioxidants (150mg of quercitin and 150mg of alpha lipoic acid)
Study: NCT02485769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Suspension

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06650833
Description: Tablet (Modified Release)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet (Modified Release)
Study: NCT03033706

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulse pressure variation guided fluid therapy
Description: Pulse pressure variation obtained from invasive blood pressure waveform

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional fluid therapy
Description: 4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Brain tumor excision
Description: Brain tumor excision under general anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Brain tumor excision
Description: Brain tumor excision under general anesthesia
Study: NCT03088397

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Decision Aid
Description: One sheet of postpartum contraceptive information arranged in a grid.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Website
Description: Patient directed to website with information on various contraceptive methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared- Decision Making Counseling
Description: Counseling using principles of shared-decision making

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared- Decision Making Counseling
Description: Counseling using principles of shared-decision making

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Shared- Decision Making Counseling
Description: Counseling using principles of shared-decision making
Study: NCT02744456

Intervention type: DRUG
Group type: OTHER
Intervention: Losartan
Description: An angiotensin II receptor antagonist drug used mainly to treat high blood pressure.

Intervention type: DRUG
Group type: OTHER
Intervention: Amlodipine
Description: A calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension.

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide
Description: A diuretic medication often used to treat high blood pressure and swelling due to fluid build up.
Study: NCT03334175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Walnuts
Description: 1 ounce of individually wrapped, raw walnuts to be consumed daily replacing a high-refined carbohydrate food.
Study: NCT03421457

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus-preserving laparoscopic lateral suspension with mesh
Description: V-shaped 2cm wide and 25cm length mesh strip is prepared from a 30x30cm Prolene mesh (Ethicon J\&J).Deep dissection of the uterovesical space is performed.Cutaneous incisions are bilaterally made 3-4 cm superoposterior to the anterosuperior iliac spine.A grasper is introduced retroperitoneally through the sub-peritoneum holding the beginning part of mesh until reaching the vesicovaginal space in an oblique route rather than transverse.Round ligament is lifted upward and tunnel is practiced horizontally.Assistant grasper catches the distal mesh and pulls out through the opposite subperitoneal tunnel.Corner of mesh is fixed to the pubocervical fascia,uterine cervix and isthmus with Absorba-Tack™(Covidien, Mansfield,USA).Tension-free lateral mesh suspension is achieved at the desired level.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus-preserving laparoscopic sacrocervicopexy with mesh
Description: The peritoneum over the sacral promontory is incised until the anterior longitudinal ligament is reached and ureters are identified. Peritoneal relaxing incision is made medial to the right ureter, down into the pelvis, posterior to the cervix and rectovaginal fascia, laterally to the rectum. The arm of the mesh is sutured to the posterior cervix by 2.0 prolene and fixated to the sacral promontory by either Tacker (Covidien) and/or 2.0 prolene as tension-free. Complete peritonisation of the mesh is performed.
Study: NCT02557997

Intervention type: OTHER
Intervention: Blood tube bottom analyses

Intervention type: OTHER
Intervention: Blood tube bottom analyses

Intervention type: OTHER
Intervention: Blood tube bottom analyses

Intervention type: OTHER
Intervention: Blood tube bottom analyses
Study: NCT00549055

Intervention type: DRUG
Intervention: Macugen
Description: Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)
Study: NCT02967445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arabin Pessary
Description: Arabin silicon pessary

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical cerclage
Study: NCT03925155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZ scrub vaginal chlorhexidine 4% solution
Description: Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% provodine-iodine vaginal preparation
Description: Patients will be randomized to receive one of two solutions. Either chlorhexidine 4% solution or standard of care 10% provodine-iodine vaginal solution
Study: NCT03772223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
Description: Randomized participants will receive a single-dose (2 inhalations, 2 x 80/90 µg).
Study: NCT01042860

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein
Description: Lutein supplement, 10 mg daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02181829

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Lung IMRT
Description: External beam radiation therapy will be administered on an outpatient basis, once daily (except weekends and holidays) for approximately two weeks. Patients will undergo a simulation prior to initiation of radiation. Once an IMRT plan is generated which meets all dose constraints specified patients will be treated with 6MV photons for 10 treatments.
Study: NCT03261622

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sacral nerve stimulation at different stimulation amplitudes
Description: Exploring the effect of different stimulation amplitude in a randomized study

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sacral nerve stimulation at different stimulation amplitudes
Description: Exploring the effect of different stimulation amplitude in a randomized study